Latham & Watkins Advises Mineralys Therapeutics in US$118 Million Oversubscribed Series B Financing

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, has announced the completion of an oversubscribed and up-sized US$118 million Series B financing. Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension. The Company anticipates releasing the top-line results of Target-HTN later this year.

Latham & Watkins LLP represented Mineralys Therapeutics with an emerging companies team led by San Diego partner Cheston Larson, with associates Christian Hollweg and Madelyn Tarr.